Adam Havey - EMERGENT BIOSOLUT President

ER4 Stock  EUR 9.49  0.01  0.11%   

President

Mr. Adam Havey is Executive Vice President Business Operations of the Company since April 2017. He previously served as executive vice president and president, biodefense division from March 2011 to March 2017. Prior to that, Mr. Havey held various roles, including president of Emergent Biodefense Operations Lansing LLC from January 2009 to February 2011, vice president of business operations from November 2007 to December 2008, and senior director of manufacturing development from June 2006 to November 2007. Prior to joining us, Mr. Havey served in product development for Eli Lilly. He received a B.S. degree in chemical engineering from Michigan State University. since 2017.
Age 48
Tenure 7 years
Havey received a B.S. in chemical engineering from Michigan State University.

Similar Executives

Found 10 records

PRESIDENT Age

Richard LaveyThe Hanover Insurance
55
Warren BarnesThe Hanover Insurance
57
Jeffrey FarberThe Hanover Insurance
58
Mark WelzenbachThe Hanover Insurance
59
John MulleadyDave Busters Entertainment
62
Ann TrippThe Hanover Insurance
60
Bryan SalvatoreThe Hanover Insurance
58
John RocheThe Hanover Insurance
59
Fernando MuletPlaya Hotels Resorts
47
Mark BerthiaumeThe Hanover Insurance
62
EMERGENT BIOSOLUT (ER4) is traded on Berlin Exchange in Germany and employs 18 people.

EMERGENT BIOSOLUT Leadership Team

Elected by the shareholders, the EMERGENT BIOSOLUT's board of directors comprises two types of representatives: EMERGENT BIOSOLUT inside directors who are chosen from within the company, and outside directors, selected externally and held independent of EMERGENT. The board's role is to monitor EMERGENT BIOSOLUT's management team and ensure that shareholders' interests are well served. EMERGENT BIOSOLUT's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, EMERGENT BIOSOLUT's outside directors are responsible for providing unbiased perspectives on the board's policies.
Robert Kramer, CFO, Interim Executive Vice President - Corporate Services Division, Principal Financial and Accounting Officer, Treasurer
Sean Kirk, Executive Vice President Manufacturing and Technical Operations
Katherine Strei, Executive Vice President, Human Resources and Communications, Chief Human Resources Officer
Fuad ElHibri, Executive Chairman of the Board
Sue Bailey, Independent Director
Jerome Hauer, Independent Director
Marvin White, Director
Kathryn Zoon, Independent Director
Atul Saran, Executive Vice President Corporate Development, General Counsel and Corporate Secretary
Seamus Mulligan, Director
George Joulwan, Independent Director
Adam Havey, Executive Vice President and Presidentident - BioDefense Division
Louis Sullivan, Independent Director
Ronald Richard, Lead Independent Director
Zsolt Harsanyi, Independent Director
Richard Lindahl, Chief Financial Officer, Executive Vice President, Treasurer

EMERGENT Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is EMERGENT BIOSOLUT a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Other Information on Investing in EMERGENT Stock

EMERGENT BIOSOLUT financial ratios help investors to determine whether EMERGENT Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in EMERGENT with respect to the benefits of owning EMERGENT BIOSOLUT security.